Tumour-derived leukaemia inhibitory factor is a major driver of cancer cachexia and morbidity in C26 tumour-bearing mice by Kandarian, Susan C. et al.
Boston University
OpenBU http://open.bu.edu
Health Sciences BU Open Access Articles
2018-12-01
Tumour-derived leukaemia
inhibitory factor is a major driver of
cancer cachexia and morbidity...
This work was made openly accessible by BU Faculty. Please share how this access benefits you.
Your story matters.
Version Published version
Citation (published version): Susan C Kandarian, Rachel L Nosacka, Andrea E Delitto, Andrew R
Judge, Sarah M Judge, John D Ganey, Jesse D Moreira, Robert W
Jackman. 2018. "Tumour-derived leukaemia inhibitory factor is a
major driver of cancer cachexia and morbidity in C26 tumour-bearing
mice." JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE, Volume 9,
Issue 6, pp. 1109 - 1120 (12). https://doi.org/10.1002/jcsm.12346
https://hdl.handle.net/2144/35945
Boston University
Tumour-derived leukaemia inhibitory factor is a major
driver of cancer cachexia and morbidity in C26
tumour-bearing mice
Susan C. Kandarian1, Rachel L. Nosacka2, Andrea E. Delitto3, Andrew R. Judge2, Sarah M. Judge2, John D. Ganey1, Jesse D.
Moreira1 & Robert W. Jackman1*
1Department of Health Sciences, Boston University, Boston, MA 02215, USA, 2Department of Physical Therapy, University of Florida, Gainesville, FL 32610, USA, 3Department
of Oral Biology, College of Dentistry, University of Florida Health Science Center, Gainesville, FL 32610, USA
Abstract
Background Cancer cachexia is a metabolic wasting syndrome that is strongly associated with a poor prognosis. The initiat-
ing factors causing fat and muscle loss are largely unknown. Previously, we found that leukaemia inhibitory factor (LIF) se-
creted by C26 colon carcinoma cells was responsible for atrophy in treated myotubes. In the present study, we tested
whether C26 tumour-derived LIF is required for cancer cachexia in mice by knockout of Lif in C26 cells.
Methods A C26 Lif null tumour cell line was made using CRISPR-Cas9. Measurements of cachexia were compared in mice
inoculated with C26 vs. C26Lif/ tumour cells, and atrophy was compared in myotubes treated with medium from C26 vs.
C26Lif/ tumour cells. Levels of 25 cytokines/chemokines were compared in serum of mice bearing C26 vs. C26Lif/ tumours
and in the medium from these tumour cell lines.
Results At study endpoint, C26 mice showed outward signs of sickness while mice with C26Lif/ tumours appeared healthy.
Mice with C26Lif/ tumours showed a 55–75% amelioration of body weight loss, muscle loss, fat loss, and splenomegaly com-
pared with mice with C26 tumours (P < 0.05). The heart was not affected by LIF levels because the loss of cardiac mass was
the same in C26 and C26Lif/ tumour-bearing mice. LIF levels in mouse serum was entirely dependent on secretion from the
tumour cells. Serum levels of interleukin-6 and G-CSF were increased by 79-fold and 68-fold, respectively, in C26 mice but only
by five-fold and two-fold, respectively, in C26Lif/ mice, suggesting that interleukin-6 and G-CSF increases are dependent on
tumour-derived LIF.
Conclusions This study shows the first use of CRISPR-Cas9 knockout of a candidate cachexia factor in tumour cells. The re-
sults provide direct evidence for LIF as a major cachexia initiating factor for the C26 tumour in vivo. Tumour-derived LIF was
also a regulator of multiple cytokines in C26 tumour cells and in C26 tumour-bearing mice. The identification of tumour-
derived factors such as LIF that initiate the cachectic process is immediately applicable to the development of therapeutics
to treat cachexia. This is a proof of principle for studies that when carried out in human cells, will make possible an under-
standing of the factors causing cachexia in a patient-specific manner.
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Introduction
Cachexia is a devastating complication of cancer. It causes
weakness, metabolic dysfunction, and intolerance to cancer
treatment.1 The loss of skeletal muscle is a clinically
significant feature of cachexia because it is a strong prognos-
ticator of mortality.1–4 Therefore, the alleviation of muscle
wasting would reduce morbidity and allow for continued can-
cer treatment. Reviews of the literature indicate that trigger-
ing factors include blood-borne proteins secreted from the
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tumour and from the patient’s response to the tumour.5–11
Tumour-derived factors that initiate cachexia must exist in
the circulation, and their identities are just beginning to be
investigated.
Pro-inflammatory cytokines and other factors are elevated
in mice and humans with cancer cachexia.6,12–14 The most
highly studied of these include interleukin-6 (IL-6) and tu-
mour necrosis factor-alpha (TNFα). However, antibodies ad-
ministered to mice or humans against these molecules have
had mixed effectiveness at improving health.6,12,14–16 More
recently, multiplex immunoassays have made possible the
measurement of many circulating factors simultaneously in
humans and in preclinical mouse models of cancer cachexia,
providing a broader picture of the growth and immune-
related factors that may play a role in cachexia.12,17,18 A diffi-
culty, however, is linking the increases in circulating factors to
a causal role in muscle wasting. In addition, different tumour
types and different animal species appear to cause wasting
by different mechanisms.14,19–22
Recently, we developed an approach to systematically iden-
tify the blood-borne factors causing cancer cachexia by rea-
soning that proteins secreted by tumours activate muscle
signalling pathways and their associated transcription factors,
which in turn regulate muscle target genes. To test this princi-
ple, we carried out a study using a medium conditioned by tu-
mour cells from the C26 colon carcinoma [C26 conditioned
medium (CM)],23 the most commonly used mouse model of
cancer cachexia. We screened for activated signalling path-
ways in myotubes treated with C26 CM and found robust acti-
vation of Stat-dependent transcription but no activation of
other commonly studied pathways in muscle. Furthermore,
genetic and pharmacological inhibition showed that
Jak2/Stat3 activation was required for C26 CM-induced
myotube atrophy. Moreover, we and others have shown that
genetic inhibition of Stat3 in skeletal muscle of C26 mice
blocks fibre atrophy.23,24 Based on these combined findings,
we assayed C26 CM for ligands belonging to the IL-6 protein
family, because this family has established activators of
Jak/Stat signalling. We subsequently performed antibody neu-
tralization studies to find that leukaemia inhibitory factor (LIF),
but not other IL-6 family members, was entirely responsible
for C26 CM-induced myotube atrophy.23 Thus, although high
levels of IL-6 induce Stat3 and a significant elevation in circu-
lating IL-6 is a common finding in mice with C26 tumours,6,25
it is not required for C26 CM-induced myotube atrophy.
Leukaemia inhibitory factor is well documented as a sur-
vival factor for mouse embryonic stem cells.26 Earlier work
on the molecular action of LIF on muscle cells showed that
it inhibits myogenesis.27,28 The anti-myogenic effect might
be related more to ERK induction than to STAT3,28 although
we showed that both STAT3 and ERK are required for the
wasting effect of LIF on muscle.23
Interestingly, in previous C26 experiments, we found in-
creased circulating levels of LIF at 19 and 25 days post-
inoculation, the latter of which was our cachexia endpoint.
This preceded the increase in circulating IL-6, which was in-
creased at 25 days, but not at 19 days.23 Furthermore, neu-
tralizing LIF in C26 CM-treated myotubes blocked the
majority of IL-6 production by cultured myotubes. These data
suggested a role for LIF in regulating cytokines such as IL-6,
found in the blood of C26 tumour-bearing mice.
Therefore, in the present study, we directly tested whether
LIF secretion by C26 tumour cells is necessary to induce ca-
chexia in vivo, in mice carrying the C26 tumour. To do this,
we employed C26Lif/ cancer cells, made using
CRISPR/Cas9, and inoculated mice with these cells compared
with C26 tumour cells. To identify circulating factors that
might be dependent on LIF, we measured levels of 23 differ-
ent cytokines or chemokines in mice with C26 or C26Lif/ tu-
mours. Our findings from this study clearly demonstrate that
LIF secreted by C26 tumour cells is required for the majority
of muscle atrophy and for cachexia-related changes in the
C26 tumour-bearing mouse. In addition, we identified several
elevated cytokines in the C26 mouse that are regulated by
C26 tumour-derived LIF.
Methods
Genetic knockout of leukaemia inhibitory factor
from C26 tumour cells
In order to remove LIF protein from the C26 tumour cell line,
we submitted C26 cells to Applied Biological Materials (ABM,
Vancouver, CA) to knock out the Lif gene using ABM’s method
of lentivirus-delivered CRISPR-Cas9. The mouse Lif gene was
targeted in a unique part of the second exon, and a bi-allelic
knockout was produced. The DNA sequencing results pro-
vided by ABM verified the two mutant alleles in the knockout
clone. The mutant alleles each had sequence deletions, one
of 2 BP and the other of 4 BP in the target site in exon 2.
We analysed the sequences against the known mouse LIF
gene data online using MacVector, in order to predict the se-
quence of the shorter peptides made in the C26Lif/ cells.
Cell culture and conditioned medium
C2C12 mouse myoblasts (American Type Culture Collection,
Manassas, VA) were maintained in growth medium (GM) con-
taining Dulbecco’s modified Eagle medium (DMEM) high glu-
cose, supplemented with penicillin–streptomycin (Invitrogen)
and L-glutamine (Invitrogen) plus 10% fetal bovine serum
(Invitrogen) and incubated at 37°C in 5% CO2. For myoblast
differentiation, cells were grown in differentiation medium
(DM) containing DMEM (plus penicillin–streptomycin and L-
glutamine) with 2% horse serum (Invitrogen) at 37°C in 5%
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CO2. C26 adenocarcinoma cells (National Cancer Institute,
Frederick, MD) were plated and maintained at 37°C and 5%
CO2, in GM.
Conditioned medium for C26 cells was made using the
methods we have published23 with modifications.7 C26 and
C26Lif/ cells were grown in GM at 37°C in 5% CO2. When
the plates reached 90% of confluence, the GM was removed,
and the cells were washed twice with sterile phosphate buff-
ered saline (PBS) and three times with DMEM with no serum
plus antibiotics and glutamine. DM was added to the cells,
and after 24 h, the medium was collected and centrifuged
in 50 mL Falcon tubes at 3645 g for 15 min at 4°C. Aliquots
of the medium were stored at 80°C for up to a year. CM
treatment of myotubes was 33% CM in DM. Treatment for
control myotubes was DM. Recombinant mouse LIF (R&D
Systems) was added to C26Lif/ CM at the same concentra-
tion (1500 pg/mL) found in C26 CM and used to treat
myotubes.
Measurement of C26 and C26Lif/ cell viability
and doubling time in culture
C26 and C26Lif/ cells were plated in 12-well tissue culture
plates at a density of 2 × 104 cells per well in GM on day 0.
Each day for 7 days, three individual wells were harvested,
and the live cell count for each was determined using the
EVE Automated Cell Counter (NanoEnTek, Waltham, MA).
Trypan blue was used to distinguish live and dead cells at
each time point. Counts were averaged for each day and plot-
ted on a logarithmic scale. Doubling time (DT) for each cell
line was calculated from the exponential phase of each
growth curve (between days 2 and 4) using the formula:
DT ¼ t log2= logC2 logC1ð Þ;
where t = 48 h, log2 = 0.3, log = log base 10, C1 = first
cell count within exponential growth phase (at day 2),
C2 = second cell count within exponential growth phase
48 h after C1.
Measurement of myotube diameter in cell culture
For all variables measured, three independent wells were
used to calculate mean values for control and treated
myotubes. Cells were grown in a six-well plate overnight be-
fore they were switched to DM. After 4 days of differentia-
tion, myotubes were photographed under phase at 20×
magnification at 0, 24, 48, and 72 h using a Nikon TS-500
inverted fluorescent microscope. DM was refreshed each
day. Six to 10 randomly selected fields per well (four wells
per group) were photographed by a Spot RT camera and Spot
Software (Diagnostic Instruments). At least 100 diameters
were measured per group using MetaMorph Imaging
software (Universal Imaging). The area of a box that was
traced along a 100 μm length of each myotube was sampled
to measure average myotube diameter.
Immunocytochemistry of myotubes
For immunocytochemistry, myotubes were fixed in 1.5%
formaldehyde in HBSS for 30 min, washed in PBS, perme-
abilized in 1% Triton X-100, washed in PBS-Tween, and then
blocked in 3% BSA in PBS-Tween. Myotubes were incubated
with mouse monoclonal anti-myosin MF20 (Developmental
Studies Hybridoma Bank, Iowa City, IA) antibody, washed,
and then incubated with goat anti-mouse fluorescein-
conjugated Alexa Fluor 488. Myotubes were visualized
through an FITC-HYQ filter, and images were taken as de-
scribed previously.
C26 inoculation and characterization in mice
All animal studies were performed with approval from the
University of Florida Institutional Animal Care and Use Com-
mittee. Prior to inoculation into mice, C26 wild-type and
knockout cells were trypsinized and washed twice with PBS
and then re-suspended in sterile 1X PBS. Tumours were pro-
duced by subcutaneous injection of both flanks with 5 × 105
cancer cells in 100 μL of PBS (106 cells total per mouse) into
8-week-old male CDF1 mice purchased from Charles River
Laboratories (Wilmington, MA). Control groups consisted of
equal volumes of 1X PBS injected into age-matched mice.
Mice were anaesthetized using inhaled isoflurane during the
procedure and administered two doses of buprenorphine im-
mediately and 12 h postoperatively. Animals were main-
tained on a 12:12 L/D cycle, were housed individually, and
were given access to food and water ad libitum. Mouse
weights and tumour diameters were measured and recorded
throughout the duration of the study. Flank tumours were
allowed to reach an endpoint of 2 cm in maximum diameter.
At this time, mice were anaesthetized using inhaled
isoflurane, a laparotomy performed, and a 27.5-gauge needle
inserted into the abdominal aorta and ~500 μL of blood with-
drawn. Blood was expressed into a gold top BD Microtainer®
blood collection tube, containing clot activator/serum sepa-
rator tube gel, inverted five times and incubated at room
temperature for 30–60 min. Samples were then centrifuged
at 2500 g for 10 min at 4°C, and separated serum removed
and stored at 80°C. One tibialis anterior (TA) and both gas-
trocnemius muscles were harvested, weighed, flash frozen,
and stored at 80°C. The other TA muscle was harvested,
weighed, embedded in OCT, and immediately frozen in
isopentane cooled in liquid nitrogen prior to storage at
80°C. The heart, spleen, tumour, and epididymal fat were
harvested and weighed. The experiment was repeated, so
leukaemia inhibitory factor drives cancer cachexia in C26 tumor mice 1111
Journal of Cachexia, Sarcopenia and Muscle 2018; 9: 1109–1120
DOI: 10.1002/jcsm.12346
there was a total of 12 mice in each of the three groups. Not
all measurements were made on all mice except for body
mass, muscle mass, and tumour mass (see figure legends).
Haematoxylin and eosin staining
Tibialis anterior muscles were equilibrated at 20°C for 1 h
prior to sectioning. A microtome cryostat was used to cut
10-μm-thick serial transverse sections, which were trans-
ferred to positively charged glass slides. The slides were then
sequentially submerged in 100% ethanol for 1 min, 70% eth-
anol for 1 min, dH20 for 2 min, and Gill’s Haematoxylin for
2 min. Sections were then washed thoroughly in dH20
followed by sequential submersions in the following solu-
tions: Scott’s Solution for 15 s, dH20 for 2 s, 70% ethanol
for 1 min, Eosin for 2 min, 95% ethanol with gentle shaking
for 1 min, 100% ethanol for 30 s, and Xylene for 3 min. Slides
were allowed to dry for 30 min and then mounted with glass
cover-slips using Permount. All sections were visualized and
images captured using a Leica DM5000B microscope (Leica
Microsystems Bannockburn, IL) and the Leica Application
Suite, version 3.5.0 software. This software was also used to
trace and measure muscle fibre cross-sectional area (CSA).
Measurement of cell culture and in vivo cytokine
and chemokine levels
Soluble analytes in mouse serum and cell culture conditioned
media were assayed using the Milliplex® Premixed 25-Plex
Mouse Immunology Multiplex Assay (Merck Millipore, Darm-
stadt, Germany) according to the manufacturer’s protocol, as
described before.17 Briefly, serum or CM was incubated in
multiscreen filter microtiter plates (EMD Millipore, San Jose,
CA) with beads coated with primary antibodies overnight at
4°C. After washing, PE-conjugated anti-cytokine antibodies
were added and incubated for an additional 2 h at room tem-
perature. Following washing, data were acquired on a
Luminex 200® system running xPONENT® 3.1 software
(Luminex, Austin, TX) and analysed using a 5-paramater logis-
tic spline-curve fitting method using Milliplex® Analyst V5.1
software (Vigene Tech, Carlisle, MA). Cytokines were quanti-
fied using a standard curve and 5-parameter logistics to de-
termine pg/mL. The analytes tested were GCSF, GMCSF,
IFNγ, IL1α, IL1β, IL2, IL4, IL5, IL6, IL7, IL-9, IL10, IL12 (p40),
IL12 (p70), IL-13, IL15, IL17, IP-10, KC, MCP1, MIP1α, MIP1β,
MIP2, RANTES, and TNFα. IL-9 and IL-17 data did not pass in-
ternal quality control standards and are eliminated from our
results.
In addition to the Milliplex assay, we used two indepen-
dent ELISA assays for LIF (R&D Quantikine MLF00, Minneapo-
lis) and IL-6 (eBioscience, Ready-Set-Go mouse, San Diego)
carried out according to the manufacturers’ protocols.
Statistics
A one-way ANOVA was used to test for overall group differ-
ences using GraphPad Prism 5.03 (GraphPad Software, La
Jolla, CA). Tukey’s post-doc test was used to identify the sta-
tistical differences between control, C26 and C26Lif/ groups
(P < 0.05). In cases where there was unequal variance or un-
equal n among the three groups, a non-parametric post hoc
test (Dunn’s) was used (P < 0.05). This is indicated in the fig-
ure legends.
Results
Bi-allelic knockout of the mouse Lif gene in C26
tumour cells
One clone of C26 called 6a had a sequence deletion mutant
on each allele: one allele had a 2 BP deletion and the other
allele had a 4 BP deletion in exon 2 (Figure 1A). This produced
a frame shift at the 47th and 46th amino acid, respectively, of
the full-length mouse LIF protein (the 24th and 23rd amino
acid of the mature secreted form of LIF) (Figure 1B). Addition-
ally, these frameshift mutants in exon 2 produced early
terminations.
C26 and C26Lif/ cell viability and doubling time
in culture
Visually, the C26Lif/ tumour cells had the same morphology
and growth characteristics as wild-type C26 cells. However,
counting the viable C26 and C26Lif/ cells over a 7 day pe-
riod the DT of viable C26 cells was 15 h during the log phase
of growth compared with 20 h for C26Lif/ cells (see Figure
S1). Cell viability of C26 cells at days 3, 4, and 5 in culture was
on average 76%, whereas C26Lif/ cell viability was 61% dur-
ing this same period of time (not shown). Cell viability during
the lag (days 1 and 2) and stationary (days 6 and 7) phases of
growth was the same among the two tumour types.
Cytokine/chemokine levels in medium conditioned
by C26 and C26Lif/ tumour cells
The levels of secreted LIF in CM from C26 and C26Lif/ cells
were 1450 pg/mL and undetectable, respectively, as mea-
sured by ELISA (Figure 2A). To determine if other secreted fac-
tors made by C26 cells were affected by knockout of the Lif
gene, selected cytokine/chemokines were measured using
multiplex analyte profiling. Medium from C26 and C26Lif/
cells was assayed and compared with culture medium without
cells. In addition to LIF, cytokines that were secreted at high
levels (>1000 pg/mL) in C26 medium were IP-10 (CXCL10),
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MCP-1, and KC (CXCL1) (Figure 2B). Cytokines that were se-
creted in moderate amounts (100–200 pg/mL) in C26 medium
were RANTES, MIP-2, and GM-CSF, and cytokines secreted at
low levels (10–50 pg/mL) in C26 medium were MIP-1α, MIP-
1β, and IL-6 (Figure 2C). Each of these cytokines, except GM-
CSF and KC, were much lower or not detected in medium from
C26Lif/ cells. The remainder of the cytokines measured in
CM had very low or not detectable levels (Table 1).
Figure 1 Location of allelic deletion mutants targeted to mouse Lif exon2. (A) The LIF nucleotide (n.t.) sequence begins in exon 2 at nucleotide 103 of
the full-length DNA sequence, excluding introns. For the clone used (‘6a’), one allele is ‘6a mutant2’, missing n.t. 138–139. The other allele is ‘6a mu-
tant4’, missing n.t. 137–140. (B) The deletion mutations caused frameshifts at amino acid 47 and 46 of the full-length protein, respectively, and early
terminations denoted by *. Amino acid sequence of wild type (mLIF), 6a mutant2, and 6a mutant 4 are shown for exon 1 and 2, and part of exon 3. The
full-length wild-type mouse LIF peptide is 203 amino acids (a.a.).
Figure 2 Cytokine concentrations in conditioned medium (CM) from C26 and C26Lif/ cells. (A) LIF. (B) IP-10, MCP-1, and KC concentration. (C)
RANTES, GM-CSF, MIP-2, MIP-1β, MIP-1α, and IL-6 concentration. ctrl = control. All values plotted (black and grey bars) are significantly greater than
control values measured in DM (not detected). The CM made was used for all experiments, and cytokine levels were measured in triplicate in all cases.
†
Significantly different from C26 value (P < 0.05).
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The effect of CM from C26 vs. leukaemia inhibitory
factor knockout (C26Lif/) tumour cells on C2C12
myotube diameter
We previously reported, using antibody neutralization, that
LIF in the C26 CM is required for myotube atrophy.23 To fur-
ther support these findings, using a genetic approach, we
compared C26 and C26Lif/ CM on myotube diameter. Fol-
lowing 24, 48, and 72 h of treatment with C26 CM, myotubes
had a significantly smaller diameter. In contrast, myotubes
did not atrophy, at any time point, in response to treatment
with C26Lif/ CM (Figure 3A–C). When LIF was added to
C26Lif/ CM at the same concentration as found in the
C26 CM (1500 pg/mL), the atrophy-inducing ability of the
C26Lif/ CM was restored (see Figure S2). These data con-
firm our previous study23 and provide further support that
C26 tumour cell-derived LIF is indispensable for myotube
atrophy.
C26 and C26Lif/ tumours in mice: effects on
tumour size, body mass, morbidity, and spleen size
In order to determine the role of tumour-derived LIF in vivo,
we inoculated mice with C26 or C26Lif/ cells and monitored
tumour growth and cachexia progression. The tumours in
mice inoculated with C26Lif/ cells grew more slowly than
mice with C26 cells, such that for a tumour endpoint diame-
ter of 1.5–2 cm, C26 tumour-bearing mice were sacrificed at
27 days post-inoculation, while C26Lif/ tumour-bearing
mice were sacrificed at 34 to 46 days post-inoculation. The
C26Lif/ mice lost less body weight over the course of tu-
mour growth compared with C26 mice (Figure 4A). Impor-
tantly, C26 mice were visibly sick at study endpoint as
evidenced by hunched posture, reduced activity and
grooming behaviour, and piloerection as commonly seen in
these mice,29 but C26Lif/ mice did not exhibit these charac-
teristics (Figure 4B). Despite the tumours from C26 and
C26Lif/ mice showing the same mass at sacrifice (Figure
4C), C26 mice had a 35% lower tumour-free body mass than
control mice, while C26Lif/ mice had an 18% lower tumour-
free body mass (Figure 4D). Therefore, the C26Lif/ mice
showed a significant 55% attenuation of cachexia compared
with C26 mice. Consistent with the notion that mice bearing
C26Lif/ tumours did not show outward signs of severe sick-
ness compared with those bearing C26 tumours, splenomeg-
aly, as measured by spleen mass, was increased by 153% in
the C26 tumour animals, whereas mice with C26Lif/ tu-
mours had a 50% increase in spleen mass (Figure 4E). This
represents a significant 65% attenuation of splenomegaly in
C26Lif/ mice.
C26 and C26Lif/ tumours in mice: effects on
muscle mass, muscle fibre size, and fat mass
Gastrocnemius muscle mass from C26 mice was 31% lower
than control mice while mass from C26Lif/ mice was 12%
lower (Figure 5A). This represents a significant 60% attenua-
tion of muscle atrophy in the C26Lif/ mice compared with
C26 mice. Similar results were seen for TA muscle mass in
tumour-bearing mice (Figure 5B). C26 mice had 33% lower
TA mass compared with control mice, while C26Lif/ mice
had a 14% lower TA mass, representing a significant 55% at-
tenuation of atrophy. Measurement of TA muscle fibre CSA
confirmed significant myofiber atrophy in C26 mice, with a
33% decrease in mean TA muscle fibre CSA (Figure 5C–E). In
C26Lif/ mice, TA fibre atrophy was significantly attenuated
by 76% compared with C26 mice. The TA fibre size frequency
distribution showed that in muscle of C26 mice, there were
more small fibres and less fibre size heterogeneity thanmuscle
from control or C26Lif/ mice. Fibre areas from C26Lif/
mice had a very similar pattern of fibre size distribution com-
pared with control mice. Mean epididymal fat mass was
650 mg in control mice and decreased to less than 50 mg in
C26 mice (Figure 5F). However, fat mass in C26Lif/ mice
was not statistically different from controls, although they
were more variable and had a mean value of 400 mg. Interest-
ingly, heart mass was decreased by 27% and 21% in C26 and
C26Lif/ mice, respectively (Figure 5G), indicating that LIF
did not significantly contribute to heart atrophy in C26 mice.
Table 1 Cytokine concentrations in differentiation medium (control) and
in medium from C26 and C26
Lif/
cells
Control C26 C26Lif/
Mean (SEM) Mean (SEM) Mean (SEM)
Cytokine n = 3 n = 3 n = 3
IP-10 n.d. 12984 (61) 824 (60)a
MCP-1 n.d. 9370 (38) 178 (2.4)a
KC n.d. 1092 (29) 1216 (23)a
RANTES n.d. 247 (18) 28 (1.4)a
GM-CSF n.d. 47 (0.7) 104 (3.3)a
MIP-2 n.d. 99 (9.2) 44 (1.9)a
MIP-1α n.d. 30 (3) 5 (3)a
MIP-1β n.d. 36 (2.4) 5.7 (1.3)a
IL-6 n.d. 28 (0.6) n.d.a
IL-5 n.d. 16 (1.1) n.d.a
G-CSF n.d. 8.7 (0.3) 3.4 (0.3)a
IL-1α n.d. 9.3 (1) n.d.a
IL-1β n.d. 4.8 (0.8) n.d.a
IL-15 n.d. 7.6 (2.4) n.d.a
IL-10 n.d. n.d. n.d.
IL-4 n.d. n.d. n.d.
IL-7 n.d. n.d. n.d.
IL-13 n.d. n.d. n.d.
IL-2 n.d. n.d. n.d.
IL-12(p40) n.d. n.d. n.d.
IL-12(p70) n.d. n.d. n.d.
IFNγ n.d. n.d. n.d.
TNFα n.d. n.d. n.d.
All values are pg/mL. SEM, standard error of the mean; n.d., not
detected.
aDifferent from C26 CM value (P < 0.05).
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Figure 3 Diameter of control (ctrl), C26 CM, and C26Lif/ CM-treated myotubes. (A) Measurements made at 0 (day 4), and 24, 48, and 72 h of treat-
ment with C26 CM or C26Lif/ CM. At least 100 myotubes were measured per group. (B) Measurement of fluorescent myotubes after immunocyto-
chemistry at 72 h treatment. (C) Representative images of fluorescent myotubes from 72 h control, C26 CM, and C26Lif/ CM-treated groups.
*
Significantly different from control value at same time point (P < 0.05).
†
Significantly different from C26 value (P < 0.05).
Figure 4 Growth characteristics of control (ctrl), C26, and C26Lif/ tumour-bearing mice (n = 12 per group). (A) Body mass during the weeks following
tumour cell inoculation. (B) Photographs of tumour-bearing mice immediately prior to sacrifice. Sacrifice was at 27 days post-inoculation for C26 mice
and 34 to 46 days post-inoculation for C26
Lif/
mice. (C) Tumour weight at sacrifice. (D) Tumour-free body mass at sacrifice. (E) Spleen mass at sac-
rifice. *Significantly different compared with control value (P < 0.05). †Significantly different from C26 value (P < 0.05). A Dunn’s post hoc test was
used for data in (D) and (E).
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C26 and C26Lif/ tumours in mice: effects on
circulating cytokine and chemokine levels
Of the 24 proteins measured in the serum of tumour-bearing
mice, only IL-12 (p40) and IL-13 were not detected by the
multiplex immunoassay. LIF was measured by ELISA.
Cytokines/chemokines that were significantly elevated in
C26 mice compared with controls were LIF, IL-6, TNFα, G-
CSF, IL-1β, IL-10, IL-2, and IP-10 (Figure 6A–H). LIF levels were
extremely low in C26Lif/ mice indicating that neither the
tumour nor the host made LIF (Figure 6A). Of the elevated
proteins in C26 mice, IL-6, TNFα, G-CFS, IL-1β, and IL-10 may
Figure 5 Muscle and fat mass in control (ctrl), C26, and C26Lif/ tumour-bearing mice. (A) Gastrocnemius muscle mass. (B) Tibialis anterior (TA) mus-
cle mass. For (A) and (B), n = 24 per group. (C) TA fibre cross-sectional areas from four muscles per group (300 fibres measured per muscle). (D) Fibre
size frequency distribution of fibre areas from TA muscle. (E) Representative photomicrograph of haematoxylin and eosin stained sections of TA muscle
from each group. (F) Epididymal fat mass. (G) Heart muscle mass. For G and H (control n = 6, C26 n = 6, C26
Lif/
n = 8).
*
Significantly different com-
pared with control value (P < 0.05). †Significantly different from C26 value (P < 0.05). A Dunn’s post hoc test was used for data in (F).
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be dependent on the secretion of tumour-derived LIF be-
cause these proteins were not significantly elevated in
C26Lif/ mice (Figure 6B–F). In contrast, the three-fold in-
crease of IP-10 in C26 mice was further increased in
C26Lif/ mice (Figure 6H). In two cases, protein levels were
unchanged in C26 mice but were significantly elevated in
C26Lif/ mice (Figure 6I, J). These proteins were MCP-1,
and most remarkably KC (Cxcl-1). In two cases (RANTES and
MIP-1β), cytokines were lower in C26 serum but were not dif-
ferent in C26Lif/ mice compared with controls (Table 2).
Circulating levels of the remaining cytokines measured, IL-7,
IFNγ, IL-4, IL-1α, IL-5, IL-12(p70), IL-15, MIP-1α, MIP-2, and
GM-CSF were not statistically different in tumour-bearing
mice compared with controls (Table 2).
Discussion
Cancer cachexia is initiated by tumour-derived factors.10
There is general consensus that many of these factors are
proteins.5,8,9,11 We previously showed that LIF is not only
sufficient to induce myotube atrophy, but it is entirely re-
sponsible for atrophy due to treatment with C26 tumour cell
CM.23 We also found a direct parallel between blood LIF
levels and cachexia in C26 tumour-bearing mice. In the pres-
ent study, we used a C26 Lif null tumour cell line to test
whether tumour-derived LIF is required for cachexia in vivo.
Importantly, we found that LIF is responsible for the majority
of cancer-induced wasting and morbidity in the C26 mouse,
and further, we identified cytokines in the circulation of these
mice that are regulated by LIF. This is the first demonstration
by CRISPR/Cas9 knockout of a tumour-derived factor that is
required for the majority of cachexia in vivo.
In cell culture, we found that in contrast to CM made from
C26 tumour cells, CM made from C26Lif/ tumour cells did
not cause myotube atrophy. This confirmed our previous
finding that a mLIF blocking antibody completely prevented
myotube atrophy due to C26 CM treatment. In mice bearing
C26Lif/ tumours, cachexia, as measured by tumour-free
body mass and the mass of organs such as epididymal fat,
spleen, and different muscle types, shows amelioration of
wasting by more than half compared with mice with C26 tu-
mours. Because wasting was not completely abolished in
Figure 6 Cytokine concentration in serum of control (ctrl), C26, and C26Lif/ tumour-bearing mice at time of sacrifice. All values are pg/mL. (A) LIF, (B)
IL-6, (C) TNFα, (D) G-CSF, (E) IL-1β, (F) IL-10, (G) IL-2, (H) IP-10, (I) MCP-1, and (J) KC. *Significantly different compared with control value (P < 0.05).
†Significantly different from C26 value (P < 0.05). For all cytokine measurements, the number of mice used were control (n = 6), C26 (n = 11), and
C26
Lif/
(n = 7). A Dunn’s post hoc test was used in all cases.
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mice with C26Lif/ tumours, this suggests that interactions
of the tumour and host produce factors that contribute to
wasting in vivo that are independent from tumour-derived
LIF.
In vivo, it was evident that the C26Lif/ tumours did not
grow as fast as C26 tumours. This is consistent with the
slower DT of C26Lif/ tumour cells (20 h) compared with
C26 cells (15 h) in culture (Figure S1). Therefore, LIF may
act either directly or indirectly, as an autocrine growth factor
for the C26 tumour in vivo. In order to study cachexia when
the two tumour types were the same size, mice with
C26Lif/ tumours were sacrificed between 1 and 2 weeks af-
ter the mice with C26 tumours, and this meant that C26Lif/
mice had tumours for a longer period of time. Nevertheless,
at the time of sacrifice, mice with C26Lif/ tumours had a
healthy appearance in contrast to severely cachectic C26
mice (Figure 3B) that consistently show hunched posture,
piloerection, reduced activity, and grooming behaviour (e.g.
other literatures29–31).
The healthier presentation of the C26Lif/ mice at the
time of sacrifice is also consistent with normalization of most
cytokines that were elevated in the C26 mice, notably LIF, IL-
6, G-CSF, IL-10, TNFα, and IL-1β. These data also suggest that
there is a dependence on LIF for the elevation of these cyto-
kines in C26 mice. Further, any atrophy in mice with Lif knock-
out tumours is not due to these cytokines because they were
not elevated. The highest levels of these putative LIF-
dependent cytokines in C26 mice were IL-6 and G-CSF. LIF
can elicit cytokine expression in multiple cell types. We
showed that it can induce IL-6 secretion in cultured
myotubes.23 It is also known to induce IL-6 secretion in
chondrocytes and blood monocytes, and it induces IL-6 in
synoviocytes, neuronal, and epithelial cells.32 The effect of
LIF on G-CSF is not previously known. The combined effect
of Lif knockout on the low levels of IL-6 and G-CSF, inducers
of white blood cell activation, may provide a molecular expla-
nation for the finding that mice with the C26Lif/ tumours
do not show outward signs of sickness compared with C26
mice. In addition, the normalization of G-CSF levels in mice
with the C26Lif/ tumours may explain the significant ame-
lioration of splenomegaly.
Our finding that IP-10, MCP-1, and KC (Cxcl-1) levels were
significantly increased in the blood of C26Lif/ compared
with C26 or control mice indicates two important points: first,
that these proteins are regulated by other factors besides LIF
in C26Lif/ mice, and second, that these chemokines may
contribute to the mild cachexia in C26Lif/ mice compared
with no-tumour controls. Increased circulating MCP-1 was re-
cently found to associate with cachexia in pancreatic cancer
patients.33 Interestingly, the increase in blood levels of
MCP-1, as well as IP-10, in mice with C26Lif/ tumours is
in contrast to the 10-fold reduction in these secreted factors
in C26Lif/ CM compared with C26 CM (Table 1) suggesting
that the increased blood levels may derive from the host
rather than the tumour. KC was unique in that it was un-
changed in C26 mice but was five-fold higher in C26Lif/
mice compared with controls. It is possible that the additional
time required to achieve the same size Lif knockout C26 tu-
mour as the wild-type C26 tumour involves longer exposure
to the inflammatory action of MCP-1, IP-10, and KC in
C26Lif/ tumour mice, thereby causing some myopathy
and mild cachexia. In this regard, we have shown that contin-
uous exposure to low doses of cachectic factors can be more
effective at muscle atrophy than larger doses applied at one
time.7 However, it is also possible that the mild cachectic fea-
tures of the C26Lif/ mice are due to factors not measured.
In contrast to skeletal muscle and adipose tissue, the
mouse myocardium appears to be unaffected by LIF levels
because heart mass was reduced by ~25% in both C26 and
C26Lif/ mice. This LIF-independent heart atrophy is consis-
tent with the study by Schafer et al. who found that Ataxin-10
in C26 tumour secretions is involved in cardiac myocyte
atrophy.5
We began to investigate LIF as a causative agent in C26
cancer cachexia because our transcription factor reporter
screening showed that only the Stat reporter was functionally
activated in muscle cells treated with C26 CM, LIF was in-
creased in C26 CM, and an LIF blocking antibody prevented
myotube atrophy.23 Now, by abolishing tumour-derived LIF
in C26 tumour-bearing mice, we provide direct support for
the hypothesis that LIF is a major cachectic factor in the
Table 2 Serum cytokine concentration from mice at the study endpoint.
Control C26 C26Lif/
Mean (SEM) Mean (SEM) Mean (SEM)
Cytokine n = 6 n = 11 n = 7
LIF n.d. 10.3 (2.8)a 0.45 (0.23)b
IL-6 8.1 (0.65) 635 (117.9)a 36.2 (8.7)b
TNFα 4.7 (0.24) 7.6 (0.33)a 5.6 (0.51)b
G-CSF 114.0 (24.1) 7793 (1363)a 222 (56.1)b
IL-1β 4.0 (0.46) 9.1 (1.1)a 5.8 (0.80)b
IL-10 6.2 (0.41) 17.0 (2.3)a 6.7 (0.65)b
IL-2 3.9 (0.25) 6.1 (0.30)a 5.2 (0.35)
IP-10 156.6 (12.6) 404 (27.2)a 631 (76.4)a,
MCP-1 27.0 (4.8) 44.7 (4.4) 64.2 (8.8)a
KC 34.3 (8.9) 13.9 (2.1) 187 (31.6)a,b
GM-CSF 9.9 (2.2) 14.0 (1.8) 7.3 (0.95)b
MIP-1β 14.9 (1.1) 10.3 (0.75)a 16.6 (1.6)b
RANTES 7.7 (1.7) 5.1 (0.18)a 7.6 (0.56)b
IL-1α 312 (15.2) 505 (95.7) 503 (87.7)
IL-5 11.7 (1.2) 7.4 (1.1) 11.1 (1.7)
IL-4 3.9 (0.10) 4.4 (0.44) 3.9 (0.07)
IFNγ 7.1 (0.92) 5.8 (0.45) 6.7 (0.64)
IL-7 8.3 (1.2) 7.7 (0.92) 8.3 (1.7)
IL-15 26.2 (6.5) 18.2 (3.4) 22.5 (4.9)
MIP-1α 22.2 (8.1) 28.4 (2.7) 23.9 (3.2)
MIP-2 155.0 (18.4) 145 (13.7) 193 (24.4)
IL-12(p70) 5.7 (0.52) 7.9 (1.5) 5.6 (0.43)
IL-12(p40) n.d. n.d. n.d.
IL-13 n.d. n.d. n.d.
All values are pg/mL.
aDifferent from control value (P < 0.05).
bDifferent from C26 CM value (P < 0.05); n.d., not detected.
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C26 mouse, and these results support that idea suggested in
several early studies that LIF may be a major cachectic factor
in nude mice bearing human LIF secreting tumour cells. Work
published as early as 1989 suggested that LIF could be a ca-
chectic factor because it was secreted from multiple human
cancer cell lines, it was a strong inhibitor of lipoprotein lipase
activity, it was sufficient to cause cachexia, and there was a
strong correlation between LIF levels and whole body wasting
in nude mice carrying LIF-secreting human tumours.34–37
These papers suggested that further studies were needed to
confirm LIF as a causative cancer cachexia factor,36,37 which
we provide here, at least in the C26 tumour-bearing mouse.
Not all preclinical models of cachexia involve LIF. The Lewis
Lung Carcinoma (LLC) is another well-studied mouse model of
cancer cachexia, and several tumour-secreted proteins, other
than LIF, have been implicated in causing wasting from
LLC.8,11 Our own evaluation of CM from LLC shows that they
secrete very low levels of LIF, not enough to contribute to
wasting (see Figure S3). In addition, recent work suggests that
active components from tumours that produce cachexia may
arise via secretion in exosomal vesicles, but these factors
have not been verified in vivo.38,39 Whether the active con-
tents are protein or inhibitory RNA, the proof of their tumour
origin for the initiation of cachexia will require ablation of the
genes responsible in the tumour itself.
In conclusion, by knocking out Lif in the C26 tumour, the
present study demonstrates that tumour-secreted LIF is re-
quired for the majority of cancer cachexia in vivo, and it impli-
cates a role of this factor in regulating other cytokines, most
notably IL-6 and G-CSF, in C26 tumour-bearing mice. This ap-
proach of gene editing tumour cells will be of great value in
leading the study of cachexia from other tumour models
and in cancer patients.
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Figure S1. The number of viable C26 and C26Lif/ cells
counted daily for 7 days. The doubling time (DT) for C26 cells
was 15 hours and for C26Lif/ cells was 20 hours.
Figure S2. Diameter of differentiated myotubes treated with
C26Lif/ CM for 3 days or C26Lif/ CM + mouse LIF
(1500 pg/mL). Myotubes at time 0 were 4-days differenti-
ated. LIF added to C26Lif/ CM rescued atrophy at 24, 48,
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CM (P < 0.05).
Figure S3. Data for mouse LIF in Lewis Lung Carcinoma (LLC)
cells. (A) Low levels of mouse LIF in differentiation medium
(DM) and in LLC medium made in DM. For comparison, mLIF
in C26 medium was 1500 pg/ml (Figure 2(A)). (B) Diameter of
myotubes treated with DM (Control) or 33% LLC conditioned
medium (CM) plus IgG or LLC CM plus mouse LIF antibody
(mLIF Ab). No effect on diameter of myotubes treated with
LLC plus mLIF antibody but complete prevention of atrophy
when myotubes treated with C26 CM plus mLIF antibody23.
*significantly different compared to control (P < 0.05).
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